Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: Applications in biotherapy

British Journal of Pharmacology

Volumn 159, Issue 4, 2010, Pages 761-771

  Baril, Patrick ^a   Martin Duque, Pilar ^b   Vassaux, Georges ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b FUNDACIÓN ARAID   (Spain)

Author keywords

Biotherapy; Cell trafficking; Gene transfer; Na I symporter; Non invasive molecular imaging; Radiotherapy

Indexed keywords

RADIOISOTOPE; SODIUM IODIDE SYMPORTER; TRACER; VIRUS VECTOR;

BIOLOGICAL MONITORING; BIOLOGICAL THERAPY; BIOLUMINESCENCE; CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; CELL THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; FLUORESCENCE IMAGING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPORTER GENE; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL; THYROID CANCER; TRANSGENE; VIROTHERAPY; VIRUS REPLICATION;

ANIMALS; BIOLOGICAL THERAPY; CELL TRANSPLANTATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBE TECHNIQUES; ONCOLYTIC VIROTHERAPY; RADIOTHERAPY DOSAGE; SYMPORTERS;

EID: 77249133123     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00412.x     Document Type: Review

References (93)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Arturi F, Ferretti E, Presta I, Mattei T, Scipioni A, Scarpelli D et al. (2005). Regulation of iodide uptake and sodium/iodide symporter expression in the MCF-7 human breast cancer cell line. J Clin Endocrinol Metab 90 : 2321 2326.
3. Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, Lu M et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 8 : 508 518.
4. Barton KN, Tyson D, Stricker H, Lew YS, Heisey G, Koul S et al. (2003). GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 8 : 508 518.
5. Blasberg RG (2003). Molecular imaging and cancer. Mol Cancer Ther 2 : 335 343.
6. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S et al. (2000). Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60 : 3484 3492.
7. Boland A, Magnon C, Filetti S, Bidart JM, Schlumberger M, Yeh P et al. (2002). Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 12 : 19 26.
8. Briat A, Vassaux G (2006). Preclinical applications of imaging for cancer gene therapy. Expert Rev Mol Med 8 : 1 19.
9. Briat A, Vassaux G (2008). A new transgenic mouse line to image chemically induced p53 activation in vivo. Cancer Sci 99 : 683 698.
10. Carlson SK, Classic KL, Hadac EM, Bender CE, Kemp BJ, Lowe VJ et al. (2006). In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol 8 : 324 332.
11. Che J, Doubrovin M, Serganova I, Ageyeva L, Beresten T, Finn R et al. (2007). HSP70-inducible hNIS-IRES-eGFP reporter imaging: response to heat shock. Mol Imaging 6 : 404 416.
12. Cheong SC, Wang Y, Meng JH, Hill R, Sweeney K, Kirn D et al. (2008). E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 15 : 40 50.
13. Chisholm EJ, Vassaux G, Martin-Duque P, Chevre R, Lambert O, Pitard B et al. (2009). Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res 69 : 2655 2662.
14. Cho YW, Park SA, Han TH, Son DH, Park JS, Oh SJ et al. (2007). In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 28 : 1236 1247.
15. Dai G, Levy O, Carrasco N (1996). Cloning and characterization of the thyroid iodide transporter. Nature 379 : 458 460.
16. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. (2005). Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 12 : 715 722.
17. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103 : 1641 1646.
18. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R et al. (2001). Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA 98 : 9300 93005.
19. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC (2005). In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 11 : 1483 1489.
20. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC (2006). Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther 17 : 661 668.
21. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F et al. (2006). Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 91 : 2389 2395.
22. Faivre J, Clerc J, Gerolami R, Herve J, Longuet M, Liu B et al. (2004). Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in Wistar rats. Cancer Res 64 : 8045 8051.
23. Fenton MS, Marion KM, Hershman JM (2008). Identification of cyclic adenosine 3′,5′-monophosphate response element modulator as an activator of the human sodium/iodide symporter upstream enhancer. Endocrinology 149 : 2592 2606.
24. Ferreira AC, Lima LP, Araujo RL, Muller G, Rocha RP, Rosenthal D et al. (2005). Rapid regulation of thyroid sodium-iodide symporter activity by thyrotrophin and iodine. J Endocrinol 184 : 69 76.
25. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M (1999). Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141 : 443 457.
26. Fritz V, Jorgensen C (2008). Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther 3 : 32 42.
27. Furuya F, Shimura H, Miyazaki A, Taki K, Ohta K, Haraguchi K et al. (2004). Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 145 : 5397 5405.
28. Garcia B, Santisteban P (2002). PI3K is involved in the IGF-I inhibition of TSH-induced sodium/iodide symporter gene expression. Mol Endocrinol 16 : 342 352.
29. Geus-Oei LF, Oyen WJ (2008). Predictive and prognostic value of FDG-PET. Cancer Imaging 8 : 70 80.
30. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT et al. (2007). Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110 : 2342 2350.
31. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G (2002). Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 13 : 1723 1735.
32. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G (2004a). Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 64 : 4906 4911.
33. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G (2004b). Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 9 : 436 442.
34. Haberkorn U, Beuter P, Kubler W, Eskerski H, Eisenhut M, Kinscherf R et al. (2004). Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. J Nucl Med 45 : 827 833.
35. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 : 255 256.
36. Hadjantonakis AK, Dickinson ME, Fraser SE, Papaioannou VE (2003). Technicolour transgenics: imaging tools for functional genomics in the mouse. Nat Rev Genet 4 : 613 625.
37. Hamstra DA, Bhojani MS, Griffin LB, Laxman B, Ross BD, Rehemtulla A (2006). Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res 66 : 7482 7489.
38. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG (2008). Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 10 : 362 370.
39. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW (2006). Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 12 : 1868 1875.
40. Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A et al. (2008a). Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res 68 : 9771 9778.
41. Hingorani M, White CL, Zaidi S, Merron A, Peerlinck I, Gore ME et al. (2008b). Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res 14 : 4915 4924.
42. Homicsko K, Lukashev A, Iggo RD (2005). RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 65 : 6882 6890.
43. Huang M, Batra RK, Kogai T, Lin YQ, Hershman JM, Lichtenstein A et al. (2001). Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 8 : 612 618.
44. Hwang DW, Jang SJ, Kim YH, Kim HJ, Shim IK, Jeong JM et al. (2008). Real-time in vivo monitoring of viable stem cells implanted on biocompatible scaffolds. Eur J Nucl Med Mol Imaging 35 : 1887 1898.
45. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A et al. (2003). Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 30 : 1077 1086.
46. Jung H (2002). The sodium/substrate symporter family: structural and functional features. FEBS Lett 529 : 73 77.
47. Kelly KA, Bardeesy N, Anbazhagan R, Gurumurthy S, Berger J, Alencar H et al. (2008). Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 5 : e85 : 0657 0668.
48. Kim HJ, Jeon YH, Kang JH, Lee YJ, Kim KI, Chung HK et al. (2007a). In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther 6 : 1130 1135.
49. Kim KI, Kang JH, Chung JK, Lee YJ, Jeong JM, Lee DS et al. (2007b). Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 48 : 1553 1561.
50. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A et al. (2003). Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 21 : 405 413.
51. Kogai T, Taki K, Brent GA (2006). Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 13 : 797 826.
52. Kogai T, Sajid-Crockett S, Newmarch L, Liu YY, Brent G (2008). Phosphoinositide-3-kinase (PI3K) inhibition induces sodium/iodide symporter expression (NIS) in rat thyroid cells and human papillary thyroid cancer Cells. J Endocrinol 199 : 243 252.
53. Lassmann M, Hanscheid H (2007). Spatial dose mapping for individualizing radioiodine treatment. J Nucl Med 48 : 2 4.
54. Lecat-Guillet N, Ambroise Y (2008). Enhanced iodide sequestration by 3-biphenyl-5,6-dihydroimidazo2,1-bthiazole in sodium/iodide symporter (NIS)-expressing cells. ChemMedChem 3 : 1211 1216.
55. Lecat-Guillet N, Merer G, Lopez R, Pourcher T, Rousseau B, Ambroise Y (2007). A 96-well automated radioiodide uptake assay for sodium/iodide symporter inhibitors. Assay Drug Dev Technol 5 : 535 5340.
56. Lee SJ, Choi KC, Han JP, Park YE, Choi MG (2007). Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas. J Endocrinol Invest 30 : 28 34.
57. Merron A, Peerlinck I, Martin-Duque P, Burnet J, Quintanilla M, Mather S et al. (2007). SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther 14 : 1731 1738.
58. Mitrofanova E, Unfer R, Vahanian N, Link C (2006). Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy. Gene Ther 13 : 1052 1056.
59. Montiel-Equihua CA, Martin-Duque P, de la Vieja A, Quintanilla M, Burnet J, Vassaux G, Lemoine NR (2008). Targeting sodium/iodide symporter gene expression for estrogen-regulated imaging and therapy in breast cancer. Cancer Gene Ther 15 : 465 473.
60. Negrin RS, Contag CH (2006). In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nat Rev Immunol 6 : 484 490.
61. Pack DW, Hoffman AS, Pun S, Stayton PS (2005). Design and development of polymers for gene delivery. Nat Rev Drug Discov 4 : 581 593.
62. Pekary AE, Hershman JM (1998). Tumor necrosis factor, ceramide, transforming growth factor-beta1, and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells. Endocrinology 139 : 703 712.
63. Penuelas I, Haberkorn U, Yaghoubi S, Gambhir SS (2005). Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging 32 (Suppl. 2 S384 S403.
64. Pittet MJ, Grimm J, Berger CR, Tamura T, Wojtkiewicz G, Nahrendorf M et al. (2007). In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci USA 104 : 12457 12461.
65. Raty JK, Liimatainen T, Unelma Kaikkonen M, Grohn O, Airenne KJ, Yla-Herttuala S (2007). Non-invasive imaging in gene therapy. Mol Ther 15 : 1579 1586.
66. Riedel C, Levy O, Carrasco N (2001). Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 276 : 21458 21463.
67. Rogers BE, Parry JJ, Andrews R, Cordopatis P, Nock BA, Maina T (2005). MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94m)Tc-Demotate 1. J Nucl Med 46 : 1889 1897.
68. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008). Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8 : 299 308.
69. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A et al. (1998). Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101 : 1296 1300.
70. Serganova I, Ponomarev V, Blasberg R (2007). Human reporter genes: potential use in clinical studies. Nucl Med Biol 34 : 791 807.
71. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A et al. (2004). Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45 : 1366 1372.
72. Shen DH, Marsee DK, Schaap J, Yang W, Cho JY, Hinkle G et al. (2004). Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 11 : 161 169.
73. Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T (1997). Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology 138 : 4493 4496.
74. Siegel E (1999). The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M.D. (1895-1955) and his celebrated patient. Cancer Biother Radiopharm 14 : 71 79.
75. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL et al. (1996). Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226 : 339 345.
76. Smit JW, Schroder-van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D et al. (2002). Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 87 : 1247 1253.
77. Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC (2000). Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60 : 6526 6530.
78. Suzuki K, Kohn LD (2006). Differential regulation of apical and basal iodide transporters in the thyroid by thyroglobulin. J Endocrinol 189 : 247 255.
79. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y et al. (1999). Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 96 : 12044 12049.
80. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA (2002). A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3′,5′-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 16 : 2266 2282.
81. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH et al. (2000). The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6 : 871 888.
82. Tjuvajev JG, Finn R, Watanabe K, Joshi R, Oku T, Kennedy J et al. (1996). Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 56 : 4087 4095.
83. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R et al. (1998). Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58 : 4333 4341.
84. Uccelli A, Moretta L, Pistoia V (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8 : 726 736.
85. Vassaux G, Groot-Wassink T (2003). In vivo noninvasive imaging for gene therapy. J Biomed Biotechnol 2003 : 92 101.
86. Waehler R, Russell SJ, Curiel DT (2007). Engineering targeted viral vectors for gene therapy. Nat Rev Genet 8 : 573 587.
87. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K et al. (2003). Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88 : 1880 1888.
88. Wenzel A, Upadhyay G, Schmitt TL, Loos U (2003). Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS. Mol Cell Endocrinol 213 : 99 108.
89. Wildner O, Morris JC (2000). The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. Cancer Res 60 : 4167 4174.
90. Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ et al. (2008). The potential of (211)Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging 35 : 1272 1281.
91. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S et al. (2003). Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 44 : 465 474.
92. Yeom CJ, Chung JK, Kang JH, Jeon YH, Kim KI, Jin YN et al. (2008). Visualization of hypoxia-inducible factor-1 transcriptional activation in C6 glioma using luciferase and sodium iodide symporter genes. J Nucl Med 49 : 1489 1497.
93. Zanzonico PB (2000). Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med 41 : 297 308.